Inogen Inc (INGN) - Total Assets
Based on the latest financial reports, Inogen Inc (INGN) holds total assets worth $285.93 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check INGN capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Inogen Inc - Total Assets Trend (2011–2025)
This chart illustrates how Inogen Inc's total assets have evolved over time, based on quarterly financial data. Check Inogen Inc (INGN) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Inogen Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Inogen Inc's total assets of $285.93 Million consist of 66.4% current assets and 33.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 34.7% |
| Accounts Receivable | $38.86 Million | 13.0% |
| Inventory | $25.97 Million | 8.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $30.76 Million | 10.3% |
| Goodwill | $10.70 Million | 3.6% |
Asset Composition Trend (2011–2025)
This chart illustrates how Inogen Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Inogen Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Inogen Inc's current assets represent 66.4% of total assets in 2025, an increase from 43.3% in 2011.
- Cash Position: Cash and equivalents constituted 34.7% of total assets in 2025, up from 16.2% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 3.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 13.0% of total assets.
Inogen Inc Competitors by Total Assets
Key competitors of Inogen Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥912.83 Million |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Dirui Industrial Co Ltd
SHE:300396
|
China | CN¥2.62 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
Inogen Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.10 | 3.07 | 5.30 |
| Quick Ratio | 2.70 | 2.67 | 4.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $129.22 Million | $135.26 Million | $265.73 Million |
Inogen Inc - Advanced Valuation Insights
This section examines the relationship between Inogen Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.05 |
| Latest Market Cap to Assets Ratio | 0.58 |
| Asset Growth Rate (YoY) | 0.8% |
| Total Assets | $298.62 Million |
| Market Capitalization | $172.46 Million USD |
Valuation Analysis
Below Book Valuation: The market values Inogen Inc's assets below their book value (0.58x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Inogen Inc's assets grew by 0.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Inogen Inc (2011–2025)
The table below shows the annual total assets of Inogen Inc from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $298.62 Million | +0.82% |
| 2024-12-31 | $296.19 Million | -9.20% |
| 2023-12-31 | $326.19 Million | -19.47% |
| 2022-12-31 | $405.04 Million | -17.26% |
| 2021-12-31 | $489.51 Million | +5.99% |
| 2020-12-31 | $461.85 Million | +3.24% |
| 2019-12-31 | $447.34 Million | +19.01% |
| 2018-12-31 | $375.90 Million | +36.65% |
| 2017-12-31 | $275.07 Million | +28.51% |
| 2016-12-31 | $214.05 Million | +32.69% |
| 2015-12-31 | $161.31 Million | +15.15% |
| 2014-12-31 | $140.09 Million | +70.01% |
| 2013-12-31 | $82.40 Million | +73.15% |
| 2012-12-31 | $47.59 Million | +97.20% |
| 2011-12-31 | $24.13 Million | -- |
About Inogen Inc
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen the… Read more